Programmable Probiotics Detect Cancer in Urine
By LabMedica International staff writers Posted on 07 Jun 2015 |
Rapid advances in the forward engineering of genetic circuitry in living cells has positioned synthetic biology as a potential means to solve numerous biomedical problems, including disease diagnosis and therapy.
A new way has been devised to detect cancer that has spread to the liver, by enlisting help from probiotics, those beneficial bacteria similar to those found in yogurt. A harmless strain of Escherichia coli that colonizes the liver has been programmed so that the bacteria produce a luminescent signal that can be detected with a simple urine test.
Bioengineers at the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) and their colleagues used a murine model and engineered a harmless strain of E. coli to express the gene for a naturally occurring enzyme called lacZ that cleaves lactose into glucose and galactose. In this case, lacZ acts on a molecule injected into the mice, consisting of galactose linked to luciferin, a luminescent protein naturally produced by fireflies. Luciferin is cleaved from galactose and excreted in the urine, where it can easily be detected using a common laboratory test.
The urine was tested for luciferin with the QuantiLum Recombinant Luciferase Kit (Promega; Madison, WI, USA) via luminescence in a Centro LB 960 Universal Microplate Luminometer (Berthold; Bad Wildbad, Germany). In tests with mice, the scientists found that orally delivered bacteria do not accumulate in tumors all over the body, but they do predictably zero in on liver tumors because the hepatic portal vein carries them from the digestive tract to the liver. This allowed the team to develop a diagnostic specialized for liver tumors. In tests in mice with colon cancer that has spread to the liver, the probiotic bacteria colonized nearly 90% of the metastatic tumors.
Sangeeta N. Bhatia, MD, PhD, a professor of health sciences and senior author of the study, said, “We realized that if we gave a probiotic, we weren't going to be able to get bacteria concentrations high enough to colonize the tumors all over the body, but we hypothesized that if we had tumors in the liver they would get the highest dose from an oral delivery.” The study was published on May 27, 2015, in the journal Science Translational Medicine.
Related Links:
Massachusetts Institute of Technology
Promega
Berthold
A new way has been devised to detect cancer that has spread to the liver, by enlisting help from probiotics, those beneficial bacteria similar to those found in yogurt. A harmless strain of Escherichia coli that colonizes the liver has been programmed so that the bacteria produce a luminescent signal that can be detected with a simple urine test.
Bioengineers at the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) and their colleagues used a murine model and engineered a harmless strain of E. coli to express the gene for a naturally occurring enzyme called lacZ that cleaves lactose into glucose and galactose. In this case, lacZ acts on a molecule injected into the mice, consisting of galactose linked to luciferin, a luminescent protein naturally produced by fireflies. Luciferin is cleaved from galactose and excreted in the urine, where it can easily be detected using a common laboratory test.
The urine was tested for luciferin with the QuantiLum Recombinant Luciferase Kit (Promega; Madison, WI, USA) via luminescence in a Centro LB 960 Universal Microplate Luminometer (Berthold; Bad Wildbad, Germany). In tests with mice, the scientists found that orally delivered bacteria do not accumulate in tumors all over the body, but they do predictably zero in on liver tumors because the hepatic portal vein carries them from the digestive tract to the liver. This allowed the team to develop a diagnostic specialized for liver tumors. In tests in mice with colon cancer that has spread to the liver, the probiotic bacteria colonized nearly 90% of the metastatic tumors.
Sangeeta N. Bhatia, MD, PhD, a professor of health sciences and senior author of the study, said, “We realized that if we gave a probiotic, we weren't going to be able to get bacteria concentrations high enough to colonize the tumors all over the body, but we hypothesized that if we had tumors in the liver they would get the highest dose from an oral delivery.” The study was published on May 27, 2015, in the journal Science Translational Medicine.
Related Links:
Massachusetts Institute of Technology
Promega
Berthold
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities